This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care
by Zacks Equity Research
UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.
Hope for Financial Market Stability: Global Week Ahead
by John Blank
Q1-23 has been rattled by bank turmoil. Some financial market stability will be much hoped for in coming days... But don't bet on it.
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens' (WBA) strategic executions on the United States and the international front is likely to have contributed to the Q2 2023 top line.
Icon PLC (ICLR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.29% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.39% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Icon PLC (ICLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ICLR vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.51% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.85% and 1.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q4 Earnings Meet Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 4.94% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts (MDRX), CareMetx Tie Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration with CareMetx to streamline specialty medication management for medical clinics and practices across the nation.